4D Molecular Therapeutics Inc (FDMT)vsMerck & Company Inc (MRK)
FDMT
4D Molecular Therapeutics Inc
$13.17
-2.37%
HEALTHCARE · Cap: $792.75M
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 72251% more annual revenue ($66.57B vs $92.01M). MRK leads profitability with a 4.8% profit margin vs -194.7%. MRK earns a higher WallStSmart Score of 36/100 (F).
FDMT
Hold36
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FDMT.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 25107.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -44.0% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : FDMT
The strongest argument for FDMT centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 25107.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : FDMT
The primary concerns for FDMT are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
FDMT profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
FDMT carries more volatility with a beta of 2.69 — expect wider price swings.
FDMT is growing revenue faster at 25107.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
FDMT scores higher overall (36/100 vs 36/100) and 25107.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
4D Molecular Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops candidate products using its adeno-associated virus vectors. The company is headquartered in Emeryville, California.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?